影像生物标志物白皮书。
White paper on imaging biomarkers.
出版信息
Insights Imaging. 2010 May;1(2):42-45. doi: 10.1007/s13244-010-0025-8. Epub 2010 May 27.
Abstract
Because of the importance of biomarkers within medicine as a whole and the increasing realisation that imaging can safely provide biomarkers, the ESR executive commissioned this report by experts in the field. It is hoped that further awareness amongst our community will contibute to further exploitation of the enormous wealth of biomaker information available in our day to day imaging. The all important issues surrounding validation and standardisation are discussed, together with proposals for a European Network on Imaging Biomarkers to oversee such aspects.
摘要
鉴于生物标志物在整个医学领域的重要性，以及人们越来越认识到成像能够安全地提供生物标志物，欧洲放射学会（ESR）管理层委托该领域的专家撰写了本报告。希望我们这个群体能进一步提高认识，从而有助于进一步利用日常成像中大量可用的生物标志物信息。文中讨论了围绕验证和标准化的所有重要问题，以及关于建立一个欧洲成像生物标志物网络以监督这些方面的提议。
相似文献
1
White paper on imaging biomarkers.影像生物标志物白皮书。
Insights Imaging. 2010 May;1(2):42-45. doi: 10.1007/s13244-010-0025-8. Epub 2010 May 27.
2
White paper of the European Association of Nuclear Medicine (EANM) and the European Society of Radiology (ESR) on multimodality imaging.欧洲核医学协会（EANM）与欧洲放射学会（ESR）关于多模态成像的白皮书。
Eur J Nucl Med Mol Imaging. 2007 Aug;34(8):1147-51. doi: 10.1007/s00259-007-0494-2.
3
White paper of the European Society of Radiology (ESR) and the European Association of Nuclear Medicine (EANM) on multimodality imaging.欧洲放射学会（ESR）和欧洲核医学协会（EANM）关于多模态成像的白皮书。
Eur Radiol. 2007 Aug;17(8):1926-30. doi: 10.1007/s00330-007-0698-7.
4
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
5
2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (Part 3 - Recommendations on 2019 FDA Immunogenicity Guidance, Gene Therapy Bioanalytical Challenges, Strategies for Critical Reagent Management, Biomarker Assay Validation, Flow Cytometry Validation & CLSI H62).《2019年生物分析近期问题白皮书：美国食品药品监督管理局免疫原性指南、基因治疗、关键试剂、生物标志物及流式细胞术验证（第3部分 - 关于2019年美国食品药品监督管理局免疫原性指南、基因治疗生物分析挑战、关键试剂管理策略、生物标志物检测验证、流式细胞术验证及临床和实验室标准协会H62的建议）》
Bioanalysis. 2019 Dec;11(24):2207-2244. doi: 10.4155/bio-2019-0271. Epub 2019 Dec 10.
6
ESR statement on the stepwise development of imaging biomarkers.欧洲风湿病学会关于成像生物标志物逐步发展的声明。
Insights Imaging. 2013 Apr;4(2):147-52. doi: 10.1007/s13244-013-0220-5. Epub 2013 Feb 9.
7
Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR).个性化医疗中的医学影像：欧洲放射学会（ESR）研究委员会白皮书
Insights Imaging. 2011 Dec;2(6):621-630. doi: 10.1007/s13244-011-0125-0. Epub 2011 Sep 29.
8
Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR).个性化医疗中的医学成像：欧洲放射学会（ESR）研究委员会白皮书
Insights Imaging. 2015 Apr;6(2):141-55. doi: 10.1007/s13244-015-0394-0. Epub 2015 Mar 13.
9
The NCI All Ireland Cancer Conference.美国国家癌症研究所全爱尔兰癌症会议。
Oncologist. 1999;4(4):275-277.
10
The ESR Patient Advisory Group (ESR-PAG).红细胞沉降率患者咨询小组（ESR-PAG）。
Insights Imaging. 2015 Apr;6(2):167-71. doi: 10.1007/s13244-015-0395-z. Epub 2015 Mar 17.
引用本文的文献
1
A Contrast-Enhanced CT-Based Deep Learning System for Preoperative Prediction of Colorectal Cancer Staging and RAS Mutation.一种基于对比增强CT的深度学习系统用于结直肠癌术前分期及RAS突变的预测
Cancers (Basel). 2023 Sep 10;15(18):4497. doi: 10.3390/cancers15184497.
2
Predictive value of F-FDG PET/CT multi-metabolic parameters and tumor metabolic heterogeneity in the prognosis of gastric cancer.18F-FDG PET/CT 多代谢参数及肿瘤代谢异质性对胃癌预后的预测价值。
J Cancer Res Clin Oncol. 2023 Nov;149(16):14535-14547. doi: 10.1007/s00432-023-05246-4. Epub 2023 Aug 12.
3
[F]-Fludeoxyglucose Positron Emission Tomography/Computed Tomography with Radiomics Analysis in Patients Undergoing Aortic In-Situ Reconstruction with Cryopreserved Allografts.[F]-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描联合影像组学分析在接受冷冻保存同种异体移植物原位主动脉重建的患者中的应用
Diagnostics (Basel). 2022 Nov 17;12(11):2831. doi: 10.3390/diagnostics12112831.
4
Evaluation of Epidermal Growth Factor Receptor 2 Status in Gastric Cancer by CT-Based Deep Learning Radiomics Nomogram.基于CT的深度学习影像组学列线图评估胃癌中表皮生长因子受体2状态
Front Oncol. 2022 Jul 11;12:905203. doi: 10.3389/fonc.2022.905203. eCollection 2022.
5
Identification of Tumor-Specific MRI Biomarkers Using Machine Learning (ML).使用机器学习（ML）识别肿瘤特异性MRI生物标志物。
Diagnostics (Basel). 2021 Apr 21;11(5):742. doi: 10.3390/diagnostics11050742.
6
Imaging biomarkers in upper gastrointestinal cancers.上消化道癌症中的影像生物标志物
BJR Open. 2019 Jun 24;1(1):20190001. doi: 10.1259/bjro.20190001. eCollection 2019.
7
Imaging for Response Assessment in Cancer Clinical Trials.癌症临床试验中的反应评估影像学。
Semin Nucl Med. 2020 Nov;50(6):488-504. doi: 10.1053/j.semnuclmed.2020.05.001. Epub 2020 Jun 10.
8
Repeatability of Quantitative Imaging Features in Prostate Magnetic Resonance Imaging.前列腺磁共振成像定量影像特征的可重复性
Front Oncol. 2020 May 7;10:551. doi: 10.3389/fonc.2020.00551. eCollection 2020.
9
Potential value of CT radiomics in the distinction of intestinal-type gastric adenocarcinomas.CT 放射组学在肠型胃腺癌鉴别诊断中的潜在价值。
Eur Radiol. 2020 May;30(5):2934-2944. doi: 10.1007/s00330-019-06629-3. Epub 2020 Feb 4.
10
Radiomics in stratification of pancreatic cystic lesions: Machine learning in action.基于影像组学的胰腺囊性病变危险分层：机器学习的实践。
Cancer Lett. 2020 Jan 28;469:228-237. doi: 10.1016/j.canlet.2019.10.023. Epub 2019 Oct 17.
本文引用的文献
1
Volumetric CT in lung cancer: an example for the qualification of imaging as a biomarker.肺癌容积 CT：影像学作为生物标志物的一个实例。
Acad Radiol. 2010 Jan;17(1):107-15. doi: 10.1016/j.acra.2009.06.019.
2
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations.磁共振扩散加权成像作为一种癌症生物标志物：共识与建议
Neoplasia. 2009 Feb;11(2):102-25. doi: 10.1593/neo.81328.
3
From darkness to light with biomarkers in early clinical trials of cancer drugs.在癌症药物早期临床试验中借助生物标志物从黑暗走向光明。
Clin Pharmacol Ther. 2009 Feb;85(2):131-3. doi: 10.1038/clpt.2008.223.
4
Liver fibrosis: challenges of the new era.肝纤维化：新时代的挑战
Gastroenterology. 2009 Feb;136(2):387-8. doi: 10.1053/j.gastro.2008.12.028. Epub 2008 Dec 25.
5
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).实体瘤新的疗效评价标准：修订的RECIST指南（第1.1版）
Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
6
Validation of novel imaging methodologies for use as cancer clinical trial end-points.用作癌症临床试验终点的新型成像方法的验证。
Eur J Cancer. 2009 Jan;45(2):290-9. doi: 10.1016/j.ejca.2008.10.030. Epub 2008 Dec 16.
7
Biomarkers in abdominal imaging.腹部影像学中的生物标志物。
Abdom Imaging. 2009 Nov;34(6):663-7. doi: 10.1007/s00261-008-9480-9. Epub 2008 Dec 2.
8
Design and endpoints of clinical trials in hepatocellular carcinoma.肝细胞癌临床试验的设计与终点
J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13.
9
The Biomarkers Consortium: on the critical path of drug discovery.生物标志物联盟：处于药物研发的关键路径上。
Clin Pharmacol Ther. 2008 Feb;83(2):361-4. doi: 10.1038/sj.clpt.6100471. Epub 2008 Jan 9.
10
Imaging biomarkers as surrogate endpoints for drug development.作为药物研发替代终点的影像生物标志物。
Eur J Nucl Med Mol Imaging. 2006 Jul;33 Suppl 1:6-10. doi: 10.1007/s00259-006-0129-z.
Zotero 插件